Bioventus

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bioventus reports Q4 revenue decline, focuses on operational efficiency

Bioventus faced revenue challenges in Q4 2022 but demonstrated strength in key segments like Surgical Solutions and international growth.
Actions taken to enhance earnings and financial stability show a commitment to improving performance and regaining investor confidence.
Challenges around revenue decline, gross margin impact, and uncertainty require strategic focus on debt management and operational efficiency.

Bioventus reports Q1 revenue growth, addresses market challenges and opportunities

Bioventus delivered solid Q1 performance with revenue growth and improved EBITDA.
Challenges in the HA market and potential divestitures were key discussion points.
Opportunities lie in revenue growth strategies, cost management, and portfolio optimization.
Overall, Bioventus aims to leverage strengths for sustained growth and profitability.

Bioventus reports Q2 growth, eyes talent acquisition for future

Bioventus showcased financial achievements in Q2 2023, with a focus on improving execution, profitability, and reducing leverage.
Despite revenue decline, the company's adjusted EBITDA increased, driven by strong volume growth in pain treatments and international segment expansion.
Management's confidence in the product portfolio, growth prospects, and talent acquisition bodes well for Bioventus's future performance and strategic direction.

Bioventus reports Q3 resilience, eyes growth in international markets

Bioventus showcased resilience with strong performance in key segments despite revenue decline.
The company's strategic focus on growth drivers and international expansion bodes well for future prospects.
Challenges in certain segments are being addressed with plans for improvement and return to growth.
2024 plans emphasize investments in sales, R&D, and portfolio optimization for sustained growth.

Bioventus reports robust Q4 earnings, sets ambitious goals for 2024

Bioventus delivered strong financial performance in Q4 2023 and outlined ambitious goals for 2024.
The company's focus on revenue growth, operational efficiency, and cash flow improvement reflects a strategic approach to value creation.
While facing debt leverage challenges, Bioventus aims to leverage its strengths and opportunities to drive sustainable growth.
Investors should monitor Bioventus' progress in executing its 2024 priorities and achieving the set financial targets.

Bioventus excels in Q1 2024, focuses on growth and profitability

Bioventus demonstrated robust performance in Q1 2024, driven by revenue growth and margin improvement.
While facing challenges in international growth and operational areas, the company remains optimistic about long-term prospects.
Management's strategic priorities and financial achievements position Bioventus well for future growth and profitability.
Analyst inquiries highlighted key areas for improvement and strategic focus for Bioventus moving forward.

Bioventus excels in Q2 2024, focuses on core growth

Bioventus reported a strong Q2 2024 with revenue growth, improved profitability, and strategic divestment decision
The company aims to drive double-digit revenue and EBITDA growth for the rest of 2024 and into 2025
Despite challenges in Restorative Therapies sales, Bioventus remains focused on core segments for growth
Enhanced financial guidance and operational efficiency position Bioventus for continued success and expansion

Bioventus posts strong Q3 results, eyes growth in medical solutions

Bioventus (BVS) reported robust Q3 results with revenue growth, improved EBITDA, and positive cash flow, reflecting operational strength and financial stability.
Strategic initiatives like the sale of the rehabilitation business demonstrate a focus on optimizing the portfolio and enhancing shareholder value.
While challenges exist in Q4 growth and business transitions, Bioventus remains well-positioned to leverage opportunities in high-demand medical solutions and international markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Full Launch of BoneScalpel® Access™ at NASS Full Launch of BoneScalpel® Access™ at NASS

Bioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago

Bioventus came in with another set of strong numbers in Q2. We reiterate the buy thesis on BVS and note there are numerous idiosyncratic risk premia on offer.

Bioventus: Reiterating Buy Thesis Following Q2 Earnings

DURHAM, N.C., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice-president and chief financial officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2022, at 11:10 a.m. ET.

Bioventus to Present at the Morgan Stanley Global Healthcare Conference

Bioventus Inc. (NASDAQ:BVS ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Dave Crawford - VP of IR Ken Reali - CEO Mark Singleton - SVP and CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Robbie Marcus - JPMorgan Drew Ranieri - Morgan Stanley Phil Coover - Goldman Sachs Operator Good morning, and welcome to the Bioventus Incorporated Second Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode.

Bioventus Inc. (BVS) CEO Ken Reali on Q2 2022 Results - Earnings Call Transcript

DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 2, 2022.

Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance

Innovative New Handpiece Addition to the Nexus Ultrasonic Generator

Bioventus Receives FDA 510(k) Clearance for SonaStar Elite

DURHAM, N.C., July 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2022 before the market opens on Thursday, August 11, 2022. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022

DURHAM, N.C., July 12, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has completed its acquisition of CartiHeal.

Bioventus Completes CartiHeal Acquisition

DURHAM, N.C., June 21, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into an amendment to the Option and Equity Purchase Agreement for its pending acquisition of CartiHeal (“Amended Acquisition Agreement”).

Bioventus Amends CartiHeal Acquisition Structure

Bioventus' diversified portfolio insulates the company from peers and enables it to innovate around its core offering. The company holds market-leading positions in several complex pain segments, offering non-invasive treatment solutions.

Bioventus: Strong Value Gap, Insulated Via Leading Market Share

Bioventus Inc. (NASDAQ:BVS ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Dave Crawford - Vice President of Investor Relations Ken Reali - Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Office Conference Call Participants Alex Nowak - Craig Hallum Operator Good day and thank you for standing by. Welcome to Bioventus First Quarter 2022 Earnings Conference Call.

Bioventus Inc. (BVS) CEO name on Q1 2022 Results - Earnings Call Transcript

DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three months ended April 2, 2022.

Bioventus Reports First Quarter Results; Reaffirms Full-Year 2022 Financial Guidance

DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that its subsidiary, Bioventus LLC, has withdrawn its offering of senior notes that was announced on Tuesday, April 26, 2022. The Company believes that current market conditions are not conducive for an offering on terms that would be in the best interests of its stakeholders. The Company is exploring alternative financing options to finance the upfront consideration of its previously announced call option to acquire CartiHeal Ltd.

Bioventus Cancels Proposed $415 Million Offering of Senior Notes; Reaffirms Full-Year 2022 Financial Guidance

DURHAM, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Cigna® commercial plans. Beginning July 1, 2022, Cigna® commercial plan members will have access to both DUROLANE and GELSYN-3, to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection and GELSYN-3, is a three-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. Durolane will be exclusive to all Cigna patients while Gelsyn-3 will be one of two multi-injection HA products under contract.

Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis

DURHAM, N.C., April 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today preliminary financial results for the first quarter ended April 2, 2022.

Bioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA

DURHAM, N.C., April 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that, subject to market conditions, its subsidiary Bioventus LLC (the “Issuer”) intends to offer for sale $415 million in aggregate principal amount of its senior notes due in 2027 (the “Notes”) in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be guaranteed by each of the Issuer's domestic restricted subsidiaries that guarantee the Issuer's obligations under its senior secured credit facilities.

Bioventus Announces $415 Million Offering of Senior Notes

DURHAM, N.C., April 25, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2022 before the market opens on Tuesday, May 10, 2022. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022

DURHAM, N.C., April 08, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that TheraSkin coverage now includes three out of the four largest commercial plans in the U.S. along with Medicare and several regional commercial plans. Bioventus' TheraSkin is a cellular and tissue-based treatment for difficult to heal chronic wounds and this expanded coverage adds more than 17 million medical lives to the existing coverage.

Bioventus TheraSkin Coverage Expands to Provide for 17 Million More Covered Lives

DURHAM, N.C., April 05, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the issuance on April 4, 2022 of previously disclosed inducement equity awards to Mark Singleton in connection with this appointment as Senior Vice President, Chief Financial Officer, and Principle Accounting Officer of the Company.

Bioventus Announces Inducement Equity to SVP Chief Financial Officer Mark Singleton

Investors aren't happy about the company's acquisition plans.

Why Bioventus Stock Is Sinking Today

DURHAM, N.C., April 04, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has exercised its call option to acquire CartiHeal Ltd., excluding the ownership interest already owned by Bioventus, for approximately $315 million, with an additional approximately $135 million payable contingent upon the achievement of $100 million in trailing twelve month sales. Bioventus plans to finance the acquisition with additional debt. The Company's decision to exercise this option follows the U.S. Food and Drug Administration's (FDA) March 29, 2022, premarket approval (PMA) of CartiHeal's Agili-C™ implant.

Bioventus Exercises Call Option to Acquire CartiHeal

DURHAM, N.C., March 16, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will participate in a fireside chat at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 22, 2022, at 11:00 a.m. ET.

Bioventus to Present at the Canaccord Genuity Musculoskeletal Conference

Bioventus Inc. (BVS) CEO Ken Reali on Q4 2021 Results - Earnings Call Transcript

DURHAM, N.C., March 10, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the fourth quarter and full-year ended December 31, 2021.

Bioventus Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Guidance

Industry Leading Peripheral Nerve Stimulator Upgraded to Improve Patient User Experience with Control of their Unique Chronic Pain Condition, Longer Battery Life Industry Leading Peripheral Nerve Stimulator Upgraded to Improve Patient User Experience with Control of their Unique Chronic Pain Condition, Longer Battery Life

News for Bioventus Stock (BVS)